

Rosanna Tarricone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3358007/publications.pdf>

Version: 2024-02-01

119
papers

3,670
citations

126907

33
h-index

149698

56
g-index

124
all docs

124
docs citations

124
times ranked

4827
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-of-illness analysis. Health Policy, 2006, 77, 51-63.	3.0	399
2	Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint <sc>ISPOR&SPE</sc> Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiology and Drug Safety, 2017, 26, 1033-1039.	1.9	251
3	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR&SPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value in Health, 2017, 20, 1003-1008.	0.3	243
4	Economic Evaluation for Devices and Drugs"Same or Different?. Value in Health, 2009, 12, 402-404.	0.3	190
5	Impact on Quality of Life of Urinary Incontinence and Overactive Bladder: A Systematic Literature Review. Urology, 2010, 75, 491-500.	1.0	182
6	Determinants of demand for total hip and knee arthroplasty: a systematic literature review. BMC Health Services Research, 2012, 12, 225.	2.2	114
7	Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review. Critical Reviews in Oncology/Hematology, 2016, 99, 13-36.	4.4	114
8	Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 69, 107-115.	1.9	71
9	An Economic Perspective on Urinary Tract Infection: The "Costs of Resignation". Clinical Drug Investigation, 2013, 33, 255-261.	2.2	69
10	Assessing the Added Value of Health Technologies: Reconciling Different Perspectives. Value in Health, 2013, 16, S7-S13.	0.3	64
11	Direct and indirect costs of schizophrenia in community psychiatric services in Italy. Health Policy, 2000, 51, 1-18.	3.0	61
12	Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. BMC Urology, 2017, 17, 4.	1.4	61
13	Challenges in the Assessment of Medical Devices: The MedtechHTA Project. Health Economics (United Kingdom) 37(10):1073-1090 (2017)	1.7	60
14	Reducing healthcare-associated infections incidence by a probiotic-based sanitation system: A multicentre, prospective, intervention study. PLoS ONE, 2018, 13, e0199616.	2.5	57
15	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget, 2016, 7, 72343-72355.	1.8	57
16	Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case"control study. BMJ Open, 2016, 6, e009669.	1.9	53
17	Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project. Pharmacoeconomics, 2015, 33, 61-69.	3.3	52
18	Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. Health Economics (United Kingdom), 2017, 26, 109-123.	1.7	52

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. <i>Clinical Drug Investigation</i> , 2016, 36, 177-194.	2.2	51
20	A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. <i>Neurourology and Urodynamics</i> , 2017, 36, 1178-1186.	1.5	49
21	Improving the Methods for the Economic Evaluation of Medical Devices. <i>Health Economics (United Kingdom)</i> , 2017, 26, 145-152.	1.7	46
22	The economic burden of stroke in Italy. The ECLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation. <i>Neurological Sciences</i> , 2005, 26, 72-80.	1.9	45
23	Harnessing Digital Health Technologies During and After the COVID-19 Pandemic: Context Matters. <i>Journal of Medical Internet Research</i> , 2020, 22, e21815.	4.3	45
24	Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review. <i>Health Policy</i> , 2016, 120, 1-15.	3.0	44
25	Key Recommendations from the MedtechHTA Project. <i>Health Economics (United Kingdom)</i> , 2017, 26, 145-152.	1.7	44
26	Impact of a probiotic-based hospital sanitation on antimicrobial resistance and HAI-associated antimicrobial consumption and costs: a multicenter study. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 501-510.	2.7	43
27	Hospital costs of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. <i>Cost Effectiveness and Resource Allocation</i> , 2010, 8, 8.	1.5	40
28	Applying health economics for policy decision making: do devices differ from drugs?. <i>Europace</i> , 2011, 13, ii54-ii58.	1.7	40
29	Diffusion and use of health technology assessment in policy making: What lessons for decentralised healthcare systems?. <i>Health Policy</i> , 2012, 108, 194-202.	3.0	39
30	De innovazione: The concept of innovation for medical technologies and its implications for healthcare policy-making. <i>Health Policy and Technology</i> , 2016, 5, 47-64.	2.5	38
31	Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation. <i>International Journal of Cardiology</i> , 2016, 209, 153-160.	1.7	37
32	The evolution of the Italian National Health Service. <i>Lancet</i> , 2021, 398, 2193-2206.	13.7	37
33	Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 707-718.	1.4	36
34	What type of clinical evidence is needed to assess medical devices?. <i>European Respiratory Review</i> , 2016, 25, 259-265.	7.1	35
35	Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 49-62.	4.4	34
36	The impact of HTA and procurement practices on the selection and prices of medical devices. <i>Social Science and Medicine</i> , 2017, 174, 89-95.	3.8	32

#	ARTICLE	IF	CITATIONS
37	Distinguishing features in the assessment of mHealth apps. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 521-526.	1.4	32
38	Cost-effectiveness analysis for trigeminal neuralgia: Cyberknife vs microvascular decompression. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 647.	2.2	29
39	Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Value in Health</i> , 2017, 20, 336-344.	0.3	29
40	Clinical outcomes and quality of life associated with the use of a biosynthetic mesh for complex ventral hernia repair: analysis of the "Italian Hernia Club" registry. <i>Scientific Reports</i> , 2020, 10, 10706.	3.3	28
41	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 95-117.	2.5	27
42	A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 37-48.	4.4	27
43	Does the approach to economic evaluation in health care depend on culture, values, and institutional context?. <i>European Journal of Health Economics</i> , 2018, 19, 769-774.	2.8	25
44	Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials. <i>Npj Digital Medicine</i> , 2021, 4, 144.	10.9	24
45	Lung Cancer App (LuCAApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. <i>BMJ Open</i> , 2019, 9, e025483.	1.9	22
46	Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies. <i>Health Policy</i> , 2021, 125, 602-608.	3.0	20
47	Oxaprozin versus diclofenac in NSAID-refractory periarthrits pain of the shoulder. <i>Current Medical Research and Opinion</i> , 2004, 20, 1279-1290.	1.9	19
48	Mobile Health Divide Between Clinicians and Patients in Cancer Care: Results From a Cross-Sectional International Survey. <i>JMIR MHealth and UHealth</i> , 2019, 7, e13584.	3.7	19
49	Measuring Value in Health Care: A Comparative Analysis of Value-based Frameworks. <i>Clinical Therapeutics</i> , 2020, 42, 34-43.	2.5	18
50	Healthcare resource consumption for intermittent urinary catheterisation: cost-effectiveness of hydrophilic catheters and budget impact analyses. <i>BMJ Open</i> , 2017, 7, e012360.	1.9	17
51	What reimbursement for coronary revascularization with drug-eluting stents?. <i>European Journal of Health Economics</i> , 2004, 5, 309-316.	2.8	16
52	Challenges in the clinical and economic evaluation of medical devices: The case of transcatheter aortic valve implantation. <i>Journal of Medical Marketing</i> , 2011, 11, 221-229.	0.2	16
53	Budget Impact Analysis of a Biosynthetic Mesh for Incisional Hernia Repair. <i>Clinical Therapeutics</i> , 2018, 40, 1830-1844.e4.	2.5	15
54	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. <i>BMC Cancer</i> , 2018, 18, 715.	2.6	15

#	ARTICLE	IF	CITATIONS
55	Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis. <i>Value in Health</i> , 2020, 23, 17-24.	0.3	15
56	Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. <i>Expert Review of Medical Devices</i> , 2020, 17, 993-1006.	2.8	15
57	Endovascular versus surgical creation of arteriovenous fistula in hemodialysis patients: Cost-effectiveness and budget impact analyses. <i>Journal of Vascular Access</i> , 2021, 22, 48-57.	0.9	15
58	Genetic Screening for the Predisposition to Venous Thromboembolism: A Cost-Utility Analysis of Clinical Practice in the Italian Health Care System. <i>Value in Health</i> , 2013, 16, 909-921.	0.3	14
59	The role of product life cycle in medical technology innovation. <i>Journal of Medical Marketing</i> , 2013, 13, 37-43.	0.2	14
60	European diabetes research and its funding, 2002â€“2013. <i>Diabetic Medicine</i> , 2017, 34, 1354-1360.	2.3	14
61	Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia. <i>European Journal of Health Economics</i> , 2019, 20, 181-193.	2.8	14
62	Impact of point of care ultrasound on the number of diagnostic examinations in elderly patients admitted to an internal medicine ward. <i>European Journal of Internal Medicine</i> , 2020, 79, 88-92.	2.2	14
63	Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e62.	0.5	14
64	Cost-effectiveness of timely versus delayed primary total hip replacement in Germany: A social health insurance perspective. <i>Orthopedic Reviews</i> , 2017, 9, 7161.	1.3	13
65	What can health systems learn from COVID-19?. <i>European Heart Journal Supplements</i> , 2020, 22, P4-P8.	0.1	13
66	Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps. <i>Health Economics (United Kingdom)</i> , 2022, 31, 73-97.	1.7	13
67	Incentivizing research into the effectiveness of medical devices. <i>European Journal of Health Economics</i> , 2016, 17, 1055-1058.	2.8	11
68	Should health technology assessment be more patient centric? If so, how?. <i>European Journal of Health Economics</i> , 2020, 21, 1117-1120.	2.8	11
69	Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 35.	1.5	11
70	What do people think about disabled youth and employment in developed and developing countries? Results from an eâ€“discussion hosted by the World Bank. <i>Disability and Society</i> , 2006, 21, 645-650.	2.2	10
71	A Probiotic-Based Sanitation System for the Reduction of Healthcare Associated Infections and Antimicrobial Resistances: A Budget Impact Analysis. <i>Pathogens</i> , 2020, 9, 502.	2.8	10
72	Economic Evaluation of Nimesulide versus Diclofenac in the Treatment of Osteoarthritis in France, Italy and Spain. <i>Clinical Drug Investigation</i> , 2001, 21, 453-464.	2.2	9

#	ARTICLE	IF	CITATIONS
73	Economic Evaluation of a New Antiemetic Drug ??? Palonosetron versus Ondansetron. <i>Clinical Drug Investigation</i> , 2005, 25, 597-608.	2.2	9
74	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. <i>Frontiers in Public Health</i> , 2020, 8, 612410.	2.7	9
75	The Costs of Pharmacological Treatment for Major Depression. <i>Pharmacoeconomics</i> , 2000, 17, 167-174.	3.3	8
76	Economic evaluation of osteoarthritis treatment in Europe. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 327-341.	1.8	8
77	The rise of rules: Will the new EU regulation of medical devices make us safer?. <i>European Journal of Internal Medicine</i> , 2020, 80, 117-120.	2.2	8
78	Costâ€“benefit Analysis in Health Care: The Case of Bariatric Surgery Compared With Diet. <i>Clinical Therapeutics</i> , 2020, 42, 60-75.e7.	2.5	8
79	Learning effect and diffusion of innovative medical devices: the case of transcatheter aortic valve implantation in Italy. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 279-292.	1.4	7
80	Venous stenting for patients with outflow obstruction and leg ulcers: costâ€“effectiveness and budget impact analyses. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 705-720.	1.4	7
81	Clinical guidelines versus current clinical practice for the management of deep vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 1334-1344.e1.	1.6	7
82	How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals. <i>Journal of Medical Economics</i> , 2008, 11, 265-279.	2.1	6
83	Current and Future Trends in the HTA of Medical Devices. <i>IFMBE Proceedings</i> , 2016, , 1345-1348.	0.3	6
84	The impacts of diabetes research from 31 European Countries in 2002 to 2013. <i>Research Evaluation</i> , 2018, 27, 270-282.	2.6	6
85	European union regulation of health technology assessment: what is required for it to succeed?. <i>European Journal of Health Economics</i> , 2022, 23, 913-915.	2.8	6
86	Setting the Scene: The Challenges of Universal Health Coverage and the Contribution of Management Education. <i>Value in Health</i> , 2013, 16, S4-S6.	0.3	5
87	Costâ€“effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 209-221.	1.4	5
88	Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients. <i>BMJ Open</i> , 2018, 8, e022291.	1.9	5
89	Economic evidence of interventions for acute myocardial infarction: a review of the literature. <i>EuroIntervention</i> , 2012, 8, P71-P76.	3.2	5
90	An Electronic Patient-Reported Outcome Mobile App for Data Collection in Type A Hemophilia: Design and Usability Study. <i>JMIR Formative Research</i> , 2021, 5, e25071.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Recommendations for the design and implementation of an Early Feasibility Studies program for medical devices in the European Union. <i>Expert Review of Medical Devices</i> , 2022, 19, 315-325.	2.8	4
92	Valutazione di convenienza economica comparata tra quetiapina e risperidone nel trattamento della schizofrenia. <i>Pharmacoeconomics Italian Research Articles</i> , 2001, 3, 27-36.	0.2	3
93	Planning and control of medical device investments by Italian public health authorities: A means to improve the decision-making process. <i>Journal of Medical Marketing</i> , 2013, 13, 135-141.	0.2	3
94	Comparative effectiveness of Mitraclip plus medical therapy versus medical therapy alone in high-risk surgical patients: a comprehensive review. <i>Expert Review of Medical Devices</i> , 2015, 12, 471-485.	2.8	3
95	Investigating Patients' Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4916.	2.6	3
96	How to Reduce Inequity of Access to Cardiac Rehabilitation After Surgical Aortic Valve Replacement. Recommendations for the Post-COVID-19 Era From a Real-World, Population-Based Study. <i>Clinical Therapeutics</i> , 2022, 44, 491-507.	2.5	3
97	Analisi economica dei costi e dei benefici dell'implementazione di un programma di prevenzione antirotavirus con il vaccino pentavalente in Italia. <i>Pharmacoeconomics Italian Research Articles</i> , 2009, 11, 1-13.	0.2	2
98	The economic impact of a medical device company's location in Italy. <i>Journal of Medical Marketing</i> , 2013, 13, 24-36.	0.2	2
99	Impatto del sistema di finanziamento a DRG sull'innovazione tecnologica in sanità. Il caso italiano. <i>Mecosan</i> , 2014, , 31-48.	0.1	2
100	Myth #5: Health Care Is Rightly Left to the Private Sector, for the Sake of Efficiency. , 2018, , 123-154.		2
101	Explaining the Health Costs Associated with Managing Intracranial Aneurysms in Italy. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 427-435.	2.1	1
102	Comparing Drug and Nondrug Technologies in Comparative Effectiveness Research. , 2016, , 275-290.		1
103	La centralizzazione degli acquisti di dispositivi medici. Metodologia per l'analisi comparativa dei capitolati di gara. <i>Mecosan</i> , 2018, , 7-26.	0.1	1
104	Delivering Effective Care Through Mobile Apps: Findings from a Multi-stakeholder Design Science Approach. <i>Lecture Notes in Computer Science</i> , 2020, , 3-14.	1.3	1
105	Pharmaco-economics and decision making in health care. The case of extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. <i>Internal and Emergency Medicine</i> , 2011, 6, 581-582.	2.0	0
106	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 1-3.	2.1	0
107	Comparing Drug and Non-drug Technologies in Comparative Effectiveness Research. , 2015, , 1-17.		0
108	Foreword. <i>Health Economics (United Kingdom)</i> , 2017, 26, 3-4.	1.7	0

#	ARTICLE	IF	CITATIONS
109	PP100 Economic Evaluation Of A New Non-Antibiotic First-line Treatment Of Recurrent Urinary Tract Infections. International Journal of Technology Assessment in Health Care, 2017, 33, 118-119.	0.5	0
110	VP55 Health Technology Assessment Of Orphan Drugs: The Case Of Hereditary Angioedema In Italy. International Journal of Technology Assessment in Health Care, 2017, 33, 173-174.	0.5	0
111	OP60 Ramucirumab In Gastric Cancer Treatment: An Economic Evaluation. International Journal of Technology Assessment in Health Care, 2017, 33, 26-27.	0.5	0
112	PP149 Assessment Of New Medical Devices With Administrative Databases. International Journal of Technology Assessment in Health Care, 2017, 33, 139-140.	0.5	0
113	VP102 The Determinants Of Diffusion Of New Technologies Across Life Cycle. International Journal of Technology Assessment in Health Care, 2017, 33, 196-196.	0.5	0
114	Basic Principles of Health Technology Assessment, Economic Evaluation, and Costing of Healthcare Programs. , 2019, , 141-156.		0
115	Il governo dell'innovazione tecnologica in sanità. Il caso dell'impianto di valvola aortica transcateretere: stato dell'arte delle indicazioni e della rimborsabilità nelle regioni italiane. Mecosan, 2016, , 137-160.	0.1	0
116	State-of-the-Art of Abdominal Wall Surgery in Italy: Coding, Reimbursement, Hospitalisations and Expenditure for Surgical Meshes. , 2019, , 87-104.		0
117	Integrating HTA Principles into Procurement of Medical Devices: The Italian National HTA Programme for Medical Devices. IFMBE Proceedings, 2020, , 1777-1782.	0.3	0
118	Approccio value-based e logiche di finanziamento: implicazioni per le politiche di rimborsabilità in sanità. Mecosan, 2020, , 83-101.	0.1	0
119	Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms. Pharmacoeconomics - Open, 2022, , 1.	1.8	0